Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17143829.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although routine clinical markers are used routinely to determine the stage of human immunodeficiency virus (HIV) disease, their use in monitoring response to antiretroviral therapy is poorly defined. Selected clinical markers were evaluated for their ability to predict first-line antiretroviral therapy success. No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy.
Medical subject headings
- Anti-HIV Agents
- Biomarkers
- Developing Countries
- HIV Infections